RSS

NHS England

NHS England has announced a landmark deal, giving children and young people access to Novartis’ Kymriah (a chimeric antigen receptor T-cell, CAR-T, therapy) — a personalised therapy for the treatment of cancer. more

News

Swedish Orphan Biovitrum (Sobi) — a pharmaceutical company that specialises in rare diseases — has secured NHS England reimbursement for its medicine for the management of urea cycle disorders (UCDs), Ravicti (glycerol phenylbutyrate). more

News

NHS England has set out its plans to simplify research processes enabling clinical trials to be fast-tracked and improving patient access. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The House of Lords Science and Technology Committee will question NHS England on the life sciences and industrial strategy as a part of its ongoing inquiry tomorrow (Tuesday 13 March). more

News

Researchers from the University of Oxford in collaboration with an intellectual property law firm have revealed that the NHS may be able to recoup over half a billion pounds from Pfizer if its Supreme Court patent appeal is unsuccessful more

News

NHS England initiative, SBRI Healthcare, has revealed which companies will benefit from its investment of £8.7 million — aimed at advancing the development of novel technologies to future-proof primary care and GP services. more

News

NHS England has called on the pharma industry to work with them on an ambitious plan to eliminate hepatitis C throughout the country five years earlier than the World Health Organisation’s (WHO’s) goal of 2030. more

News

NHS England has revealed that thousands of patients have benefited from the new CDF and as a result of discounts it has secured on eight treatments, savings of around £140 million should be generated over the course of the next five years more

News

Global pharmaceutical company, Mylan, is joining in the battle to prevent HIV infection by delivering the world’s biggest pre-exposure prophylaxis (PrEP) implementation trial, which will target an estimated 10,000 high risk people. more

News

NHS England’s funded programme, Small Business Research Initiative (SBRI) Healthcare, has been recognised as ‘the best role model’ in an independent review by David Connell. more

News

Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today. more

News

A new statement has been released based on a decision of the Board of the Association of the British Pharmaceutical Industry (ABPI) that it will not appeal the outcome of its judicial review application versus NICE more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Speaking at Expo conference in Manchester, the head of NHS England, Simon Stevens, unveiled an ambitious plan for the NHS as it approaches its 70th anniversary. more

News

PrEP drugs

Shutterstock.com

A three-year trial of the pre-exposure prophylaxis (PrEP) for the prevention of HIV infection has been announced by NHS England and will be the largest single study of its type in the world with an estimated 10,000 people expected to be included. more

News

NHS England has struck a deal with Roche and endorsed by the National Institute for Health and Care Excellence (NICE) to make the breast cancer drug Kadcyla available for routine use on the NHS. more

News

SBRI Healthcare has announced the latest awards in the NHS England funded initiative to develop innovative products that address unmet health needs. more

News

A survey of leading pharmaceutical businesses in the UK has led to a stark warning about a potential decrease in access to new medicines in the UK. more

News

The Association of the British Pharmaceutical Industry (ABPI) has responded to NHS England and NICE’s proposed £100,000 quality-adjusted life year (QALY) threshold for medicines. more

News